Mein Warenkorb

TLR3

TLR3 Molekülinformation

Englischer NameToll like receptor 3Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel7Target-AliasCD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameToll like receptor 3
Target-AliasCD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphaseApproved

TLR3 Produktliste

  • Attribut

    Protein (3)Cell (1)

  • Produktbibliothek

    Online (3)In Forschung (1)

  • Spezies

    Human (2)Mouse (1)Rhesus macaque (1)

  • Etikett

    Fc Tag (3)- (1)

  • Marker

    Unconjugated (3)- (1)

TLR3 Molekülalias

TLR3,CD283,IIAE2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TR-987Z-101; GLYC-101; MG-3601; TR-987Phase 3 ClinicalKazia TherapeuticsVaricose Ulcer; Varicose Veins; Wounds and Injuries
Details
Monovalent norovirus Vaccine (Vaxart)VXA-G1-1-NN; VXA-G1.1-NNPhase 2 ClinicalVaxart IncNorovirus Infections
Details
Poly ICLC (Oncovir)Phase 2 ClinicalNational Institutes Of Health, Oncovir IncBreast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Esophageal Neoplasms; Glioma; HIV Infections; Low-grade Glioma; Lymphoma, B-Cell; Lymphoma, T-Cell; Melanoma; Mesothelioma; Metastatic breast cancer; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
BO-112BO-112Phase 2 ClinicalHighlight Therapeutics SLCarcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dermatofibrosarcoma; Esophageal Neoplasms; Fibrosarcoma; Histiocytoma, Malignant Fibrous; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neurofibrosarcoma; Rhabdomyosarcoma; Sarcoma; Sarcoma, Synovial; Stomach Neoplasms
Details
Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NSVXA-NVV-201Phase 2 ClinicalVaxart IncNorovirus Infections
Details
CNTO-5CNTO-5Phase 1 ClinicalMorphosys AgInflammation
Details
PGV-001PGV-001Phase 1 ClinicalGenentech Inc, Icahn School Of Medicine At Mount SinaiNeoplasms; Urologic Neoplasms
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
RintatolimodAMP-516; AMP-518ApprovedHemispherx Biopharma IncRintamod, AmpligenArgentinaFatigue Syndrome, ChronicHemispherx Biopharma Inc2017-01-01Breast Neoplasms; Breast Neoplasms, Male; Colorectal Neoplasms; Fatigue Syndrome, Chronic; HIV Infections; HIV Seropositivity; Influenza, Human; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Post-Acute COVID-19 Syndrome
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns